On January 18, 2022 – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and PersonGen BioTherapeutics, a Chinese biotech company at clinical trial stage, which is developing breakthrough and innovative CAR-T cell therapies for solid tumors and hematologic tumors, reported a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating PersonGen’s TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgene’s Invir (Press release, Transgene, 18 18, 2022, View Source [SID1234605602]). IO platform, in solid tumors including pancreatic cancer and brain glioma. The collaboration aims to demonstrate the combination’s likely synergistic mechanisms to potentiate CAR-T cell therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the collaboration agreement, Transgene will develop multiple new OV
candidates, using its patented oncolytic virus backbone VVcopTK-RR- and its Invir.IO technology
platform, specifically for IV administration in combination with PersonGen’s TAA06 CAR-T
injection. PersonGen will evaluate the efficacy of the combination to eliminate solid tumors in
preclinical models.
While CAR-T cell drugs have achieved great success in the treatment of hematological tumor
therapies, there are many clinical challenges with the use of these novel therapies to treat solid
tumors. One of the most critical obstacles is that the solid tumor microenvironment not only
obstructs the homing of CAR-T cells, but also inhibits CAR-T cells’ function. In addition, the high
heterogeneity of solid tumors also facilitates immune escape from CAR-T cell therapy.
TAA06, has been independently developed by PersonGen, which has filed an investigational new
drug (IND) application for this novel CAR-T therapy in China and will initiate the IND in the US later
this year. Preclinical studies with TAA06, including pharmacodynamic data have shown superior
in vivo and in vitro therapeutic efficacy in solid tumors.
Patented VVcopTK-RR- oncolytic viruses developed with Transgene’s Invir.IO platform are able to:
• selectively replicate in cancer cells leading to tumor lysis; effectively release antitumor payloads into the tumor;
• stimulate an immune response locally in the tumor, thus optimizing the safety profile
of the virus with the added potential to transform a "cold" tumor into a "hot" tumor.
Clinical and preclinical data has demonstrated that after IV administration, VVcopTK-RR- oncolytic
viruses selectively replicate and persist in tumor cells leading to the local expression of its
functional payload*
.
Based on these highly supportive data, Transgene and PersonGen believe that combining
Transgene’s OV and PersonGen’s CAR-T therapies could overcome the challenges of solid tumor
heterogeneity by improving the tumor microenvironment.